Game On Mole is back this summer!

Game On Mole is back this summer!

13 November 2020

The edgy Game On Mole campaign leverages the iconic Aussie catch-cry ‘game on, mole’, encouraging young Australians to check their skin for changes and then seek medical advice if they notice any changes.

It calls on Aussies to don a limited-edition ‘Game On Mole’ T-shirt and share selfies on social media tagged #gameonmole to generate life-saving conversations around sun safety and skin health.

With one Australian expected to be diagnosed with melanoma every half an hour this year, Olympian and melanoma survivor, Cate Campbell, is once again fronting the campaign.

‘I am living proof that early detection is vital to saving lives from melanoma. We need to be having discussions about sun-safety and checking your skin for changes, and I encourage all Aussies to buy a t-shirt, wear it proudly, and start those life-saving conversations.’  

CEO of Melanoma Institute Australia, Matthew Browne, said the campaign uses Australian humour to relay a serious message.

‘We know Australians love a laugh almost as much as they love soaking up the sun. But melanoma is no laughing matter, with one Australian dying from the disease every five hours and it being the most common cancer impacting 15 to 39 year olds.
‘The strength of this campaign lies in its capacity to empower all Australians to be a part of the solution by wearing a t-shirt that begs the question ‘what is that about?’ It’s a great conversation starter about what is largely a preventable disease.’

This year’s campaign includes a range of new t-shirt designs giving people a variety of ways to spread the ‘Game On Mole’ message. T-shirt sales also help fund ongoing research by Melanoma Institute Australia into new treatments to save lives from melanoma.

Go to www.gameonmole.com.au to buy the t-shirt and for life-saving information. Follow the campaign on socials on facebook and Instagram.

For more information, please contact:
Jennifer Durante |Melanoma Institute Australia | 0412 798 990 | jennifer.durante@melanoma.org.au

MIA contributes to major research breakthrough which pioneers a new way of treating cancer
01 Jun 2015

MIA contributes to major research breakthrough which pioneers a new way of treating cancer

The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.

Q&A with our Clinical Research Fellow
26 May 2015

Q&A with our Clinical Research Fellow

We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam

International Clinical Trials Day marked
20 May 2015

International Clinical Trials Day marked

Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research. 

5 minutes with Practice Manager Sherrie D'Souza
15 May 2015

5 minutes with Practice Manager Sherrie D'Souza

We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role. 

Associate Professor Georgina Long has won the InStyle Women In Style Award
14 May 2015

Associate Professor Georgina Long has won the InStyle Women In Style Award

Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category. 

The Federal Government's 2015-16 Budget announcements benefit research
14 May 2015

The Federal Government's 2015-16 Budget announcements benefit research

The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding. 

Professor Thompson made an honorary member of the American Surgical Association
01 May 2015

Professor Thompson made an honorary member of the American Surgical Association

The Association's members include prominent surgeons from around the world. 

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
20 Apr 2015

MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients

This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers. 

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA®) has been registered by the TGA
20 Apr 2015

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA® ) has been registered by the TGA

Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.

MIA's Autumn Newsletter
12 Apr 2015

MIA's Autumn Newsletter

Our Autumn newsletter has been published and we have our digital version online now. 

Professor John Thompson appointed to Australian Academy of Health and Medical Sciences
31 Mar 2015

Professor John Thompson appointed to Australian Academy of Health and Medical Sciences

Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.

Melanoma Institute part of $14m melanoma project grant
25 Mar 2015

Melanoma Institute part of $14m melanoma project grant

Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.

Melanoma March Bibs
19 Mar 2015

Melanoma March Bibs

If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day. 

Manly Melanoma March
17 Mar 2015

Manly Melanoma March

Manly Melanoma March has changed to a new location. 

Q&A with Melanoma March Fundraisers
10 Mar 2015

Q&A with Melanoma March Fundraisers

We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips. 

Research Director Graham Mann explains where Melanoma March funds are going
10 Mar 2015

Research Director Graham Mann explains where Melanoma March funds are going

We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.

First patient recruited to the EAGLE FM Trial
09 Mar 2015

First patient recruited to the EAGLE FM Trial

Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.  

Online Comments to the Pharmaceutical Benefits Advisory Committee
09 Feb 2015

Online Comments to the Pharmaceutical Benefits Advisory Committee

You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.

A man of commitment
06 Feb 2015

A man of commitment

Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.